Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Kestrel Therapeutics, Inc.
Boehringer Ingelheim
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
IDEAYA Biosciences
Pfizer
Revolution Medicines, Inc.
Stanford University
Conjupro Biotherapeutics, Inc.
DeuterOncology
City of Hope Medical Center
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
University Hospital Heidelberg
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Emory University
H. Lee Moffitt Cancer Center and Research Institute
Pheon Therapeutics
Mayo Clinic
Eli Lilly and Company
Whitehawk Therapeutics, Inc.
University of Vermont
National Cancer Institute (NCI)
SystImmune Inc.
Pfizer
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Conjupro Biotherapeutics, Inc.
Mayo Clinic
RasCal Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Fred Hutchinson Cancer Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center